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It is hypothesized that different ligand-induced
conformational changes can explain the different
interactions of nuclear receptors with regulatory
proteins, resulting in specific biological activities.
Understanding the mechanism of how ligands reg-
ulate cofactor interaction facilitates drug design.
To investigate these ligand-induced conforma-
tional changes at the surface of proteins, we per-
formed a time-resolved fluorescence resonance
energy transfer assay with 52 different cofactor
peptides measuring the ligand-induced cofactor
recruitment to the retinoid X receptor- (RXR) in
the presence of 11 compounds. Simultaneously we
analyzed the binding modes of these compounds
by molecular docking. An automated method con-
verted the complex three-dimensional data of li-
gand-protein interactions into two-dimensional
fingerprints, the so-called ligand-receptor interac-
tion profiles. For a subset of compounds the con-
formational changes at the surface, as measured
by peptide recruitment, correlate well with the cal-
culated binding modes, suggesting that clustering
of ligand-receptor interaction profiles is a very use-
ful tool to discriminate compounds that may in-
duce different conformations and possibly differ-
ent effects in a cellular environment. In addition,
we successfully combined ligand-receptor interac-
tion profiles and peptide recruitment data to reveal
structural elements that are possibly involved in
the ligand-induced conformations. Interestingly,
we could predict a possible binding mode of
LG100754, a homodimer antagonist that showed
no effect on peptide recruitment. Finally, the ex-
tensive analysis of the peptide recruitment profiles
provided novel insight in the potential cellular ef-
fect of the compound; for the first time, we showed
that in addition to the induction of coactivator pep-
tide binding, all well-known RXR agonists also
induce binding of corepressor peptides to RXR.
(Molecular Endocrinology 21: 30–48, 2007)
THE COMMUNICATION BETWEEN different func-tional sites of a protein is essential in the regulation
of the various activities commonly displayed by each
protein. The biological response in the cell is not de-
fined by the activity of each of the different functional
sites in the protein separately, but from the effective
coupling of those diverse signals. The nuclear receptor
(NR) ligand-binding domain (LBD) is well suited to the
study of this communication because this domain has
three distinct functional sites: 1) the ligand-binding
pocket (LBP) that accommodates the ligand; 2) the
cofactor binding groove that facilitates binding of
(de)activating regulatory proteins; and 3) the dimeriza-
tion interface that allows for the interaction with other
NRs. The LBD is a module of the full-length NR, which
is a ligand-activated transcription factor with a com-
mon architecture (1–3). NRs consist of an N-terminal
domain that contains the ligand-independent activa-
tion function 1 (AF-1), a central DNA-binding domain
and a C-terminal LBD that harbors the important li-
gand-dependent activation function 2 (AF-2). In gen-
eral, NRs are activated by binding of an agonist in the
LBP of the LBD, which leads to stabilization of the
AF-2 helix [also called helix 12 (H12)] in the agonist
position (4–6). The movement of H12 facilitates the
formation of the cofactor binding groove (7). Coacti-
vators bind into this groove with a short helix that
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contains a LXXLL sequence motif (NR box) (7–9). In
contrast, an antagonist displaces H12, resulting in the
dissociation of coactivators and the association of
corepressors. Corepressors bind into the cofactor
binding groove similarly to coactivators, but with a
LXX(I/H)IXXX(I/L) sequence motif (10–12). The only
available crystal structure with a corepressor shows
that the corepressor peptide position is slightly tilted
so that it partially overlaps with the agonistic location
of H12 (10). Subsequently, the receptor-cofactor com-
plex binds as a homodimer, heterodimer, or monomer
to NR-specific response elements in the promoter re-
gion of target genes, which results in up- or down-
regulation of those genes.
The above described mechanism suggests that
agonists and antagonists induce two distinct confor-
mational states of the LBD, i.e. stabilizing H12 in the
agonist or antagonist position, respectively. These dis-
tinct conformations lead to the interaction with coac-
tivators or corepressors and result in two distinct pat-
terns of gene expression. However, it was observed
that different agonists induce different gene expres-
sion profiles (13, 14). This may suggest that H12 does
not have two distinct positions but can take any pref-
erential position between the distinct agonist position
and antagonist position. It is the combination of both
compound and cofactor that determines the position
of H12 and therefore the effect on gene expression.
This suggests the existence of a more subtle commu-
nication pathway between the LBP and the cofactor
binding groove of the NR. It has been shown for the
estrogen receptor (ER)  and the peroxisome prolif-
erator-activated receptor- (13, 15) that the binding of
different ligands results in distinct patterns of cofactor
binding. The cofactors in those studies are mimicked
by helical peptides of 20–25 amino acids, containing
the LXXLL coactivator motif or the LXX(I/H)IXXX(I/L)
corepressor motif. These different patterns of peptide
binding, so-called peptide recruitment profiles, are
most likely caused by different conformations at the
NR surface, in particular the cofactor binding groove.
These studies show that peptide recruitment profiles
are very useful to probe the conformation at the NR
surface and to study the position of H12 in the pres-
ence of ligand and cofactor peptides. Moreover, com-
pounds can be clustered according to their similarity in
peptide recruitment profiles. It is believed that com-
pounds in one peptide recruitment cluster induce sim-
ilar conformations at the NR surface, which may result
in transcription of the same set of target genes. From
a structure-based drug design perspective it is there-
fore important to know which interactions between
ligand and receptor cause a specific NR surface con-
formation, i.e. peptide recruitment profile. In other
words, molecular understanding of the communica-
tion between LBP and cofactor binding groove may be
one step further toward the design of NR drugs with a
certain gene transcription profile.
In this paper we describe a methodology that helps
to obtain this molecular understanding of ligand-in-
duced conformations of the NR surface. We first mea-
sured peptide recruitment profiles for a set of different
ligands. Second, we studied whether these different
ligands actually have distinct binding modes using the
available X-ray structures and docking. The different
binding modes of compounds were represented by
so-called ligand-receptor interaction profiles, thereby
converting complex three dimensional (3D) data into
two-dimensional fingerprints. These ligand-receptor
interaction profiles were used to cluster compounds
that bind in a similar manner. Finally we compared the
clusters of the peptide recruitment profiles with the
clusters of the ligand-receptor interaction profiles to
reveal residue positions that are involved in signaling
between the LBP and the surface of the LBD.
As a representative of the NRs we used the retinoid
X receptor (RXR) . RXRs (16) are unique within the NR
superfamily because they form heterodimers with
many other NRs and also function autonomously, as
homodimers (17). The receptors are involved in impor-
tant processes such as the regulation of carbohydrate
and lipid metabolism, cell differentiation, proliferation,
and morphogenesis. RXRs are regulated by retinoids,
which are derivatives of vitamin A. The natural ligand
of these receptors is 9-cis retinoic acid (9-cis RA) (18).
Another class of RXR ligands comprises fatty acids,
e.g. oleic acid, docosa hexaenoic acid (DHA), and
phytanic acid (19–21). Finally, there are many synthetic
ligands known for RXR (22), some of which are cur-
rently available as drugs for the treatment of (skin)
cancers and dermatological diseases, such as psori-
asis and acne.
In this study the induced peptide recruitment pro-
files of 10 well-described RXR ligands [and one reti-
noic acid receptor (RAR) ligand, TTNPB] were deter-
mined using a time-resolved fluorescence resonance
energy transfer (TR-FRET) assay with 52 peptides.
Simultaneously, the binding modes of these ligands in
the pocket of RXR were determined by modeling and
molecular dynamics (MD) simulations. Clustering of
the peptide recruitment profiles revealed that the com-
pounds induced three distinct conformations at the
surface of the LBD. Clustering of the binding modes
showed two distinct modes of ligand binding for the
RXR compounds. We successfully combined ligand
binding profiles and peptide recruitment profiles to
reveal structural determinants of signaling from the
LBP to the surface of the LBD.
RESULTS
To investigate whether different RXR ligands induce
different conformations at the RXR LBD surface, we
performed a peptide recruitment assay with 52 pep-
tides (107 M) and 11 different ligands (105 M). The
resulting peptide recruitment profiles are depicted in
Fig. 1. Figure 1A shows the raw fluorescence intensity
data. This figure shows that approximately half of the
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Fig. 1. Peptide Recruitment Profiles of RXR LBD Induced by Different Ligands
A, Binding of 52 biotinylated peptides (0.1 M) to GST-labeled hRXR LBD (10 nM) in the absence (dotted line) and presence
of 10 M 9-cis RA (solid line). The SEM of two separate experiments, each performed in duplicate, is indicated by the error bars.
B, Peptide recruitment profiles of 11 RXR ligands: the association and dissociation of 52 peptides to hRXR LBD is represented
as log(MI) values. The modulation index (MI) was obtained by dividing the fluorescence intensity in the presence of ligand by the
intensity in the absence of ligand. Each line represents the average peptide recruitment profile for one of the 11 compounds. The
SEM for each profile is given in supplemental Fig. 1 published as supplemental data on The Endocrine Society’s Online Journals
web site. The average peptide recruitment profile of 9-cis RA is highlighted as a black solid line. Peptides have been divided in
coactivators or corepressors on the basis of their sequence motif.
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peptides already bind to the RXR surface in the ab-
sence of ligand (dotted line). The majority of these
peptides are derived from coactivators. This suggests
that H12 is stabilized in the agonist position in the
absence of ligand, which is also observed in several
NR LBD apo crystal structures (e.g. Refs. 23–27). Most
likely, these peptides bind so well in the cofactor bind-
ing groove that they stabilize H12 in the agonist posi-
tion (and vice versa). Figure 1A also shows the peptide
recruitment profile in the presence of 9-cis RA, the
natural ligand of RXR (solid line). For many peptides,
the fluorescence intensity, which is a measure of the
peptide binding to the LBD, is higher in the presence
of 9-cis RA. This indicates that the affinity of these
peptides is increased due to the binding of 9-cis RA in
the LBP.
Because the basal ligand-independent signal varies
between different peptides, it is difficult to easily com-
pare the effect of the ligand. For this purpose, the
log[modulation index (MI)] was calculated (see TR-
FRET Assay in Materials and Methods for more de-
tails), and the resulting peptide recruitment profile of
9-cis RA is depicted in Fig. 1B (black line). This repre-
sentation directly shows whether a compound is as-
sociative or dissociative. Values above zero indicate
recruitment of peptides, and thus an associative effect
of the ligand on peptide binding. In contrast, values
below zero indicate dissociation of peptides and
therefore a dissociative effect of the compound on
peptide binding. A log(MI) value of approximately zero
means that the peptide does not bind or that the
binding of a peptide is hardly changed by the ligand.
Peptides that Do Not Bind in the Absence and
Presence of 9-cis RA
The peptide recruitment profile of 9-cis RA in Fig. 1B
(dark line) shows that 25 peptides have a log(MI) value
of approximately zero (log(MI) 0.1). Of these 25 pep-
tides, 12 also do not bind in the absence of 9-cis RA
(Fig. 1A), indicating that these peptides are not com-
patible with the RXR cofactor binding groove. These
12 peptides include six peptides with a corepressor
motif (NcoR_1, NCoR_2, BL29, HR_1, HR_2, BT_1)
and six peptides with a coactivator motif (SRC3_4,
ASC2_2, ARA70, Ppt4–1, LXR_H12, and FHL2). A
sequence alignment of the six nonbinding corepressor
peptides revealed no sequence similarity that explains
why these peptides do not bind (data not shown). The
alignment of the six nonbinding coactivator peptides
(Fig. 2A) showed that three coactivator peptides do
not have a LXXLL motif but a FXXL(F/Y) motif. Several
studies showed that the FXXL(F/Y) motif is preferred
by the androgen receptor to interact with coactivators,
whereas other NRs show no affinity for peptides with
this motif (28–30). Moreover, all six peptides possess
a polar residue at the 1 position relative to the co-
activator motif (LXXLL). This observation agrees well
with previous studies, which showed that a hydropho-
bic residue is preferred at this position to facilitate
proper coactivator binding to various NR LBDs (31,
32). This hydrophobic residue at the 1 position is
locked in an aromatic region of RXR that is induced
by the peptide (33). A polar residue at the 1 position
is therefore unfavorable.
Peptides that Bind in the Absence of Ligand but
Are Not Inducible by 9-cis RA
Figure 1, A and B, shows that the remaining 13 pep-
tides equally bind to RXR with and without 9-cis RA.
These data suggest that these peptides bind so
strongly to the RXR LBD that this interaction cannot
be further enhanced by 9-cis RA. This is confirmed by
the dose-response curves of one of these peptides
[receptor interacting protein (RIP)140_3], shown in Fig.
3A. The estimated Kd
app values of the dose-response
curves in the absence and presence of 9-cis RA are
nearly equal (152 nM in the absence and 155 nM in the
presence of compound), which indicates that there is
no effect on the peptide binding by 9-cis RA.
Figure 2B shows the sequence alignment of these
13 strong binding peptides. Except RIP140_3, all pep-
tides contain both the LXXLL motif and the favorable
hydrophobic residue at the 1 position (31–33). Ob-
viously, this is one of the essential structural properties
that coactivator peptides need: to bind so strongly to
the LBD that binding of 9-cis RA is no longer required.
RIP140_3 is the only peptide without the hydrophobic
residue at the 1 position. This suggests that other
residues in the coactivator peptide compensate for the
absence of the hydrophobic residue. One possible
explanation could be the lysine at position 2 that may
have a favorable electrostatic interaction with aspar-
tate 295 in the coactivator binding groove. This is
corroborated by the observation that the four top-
ranked peptides (in the absence of ligand) all contain a
positive charge or H-bond donor at position 2 in the
coactivator motif.
Peptides Whose Binding Is Inducible by 9-cis RA
Finally, there is a set of 17 peptides that weakly or not
bind in the absence of ligand and bind (log(MI) 0.30,
i.e. 2-fold increase in fluorescence intensity) signifi-
cantly better in the presence of 9-cis RA. Some of
these peptides have been described in previous stud-
ies to interact with RXR. For example, our observa-
tion that RIP140_7 is significantly enhanced in binding
to the receptor upon addition of 9-cis RA agrees well
with a study of Farooqui et al. (34). Also the observa-
tion that the interaction of SHP_2 with the LBD is
enhanced with 9-cis RA is in agreement with previous
studies (35). Surprisingly, upon addition of the agonist
9-cis RA, there is also a significant increase in the
affinity of four corepressor peptides [NCoR_3L, silenc-
ing mediator of retinoid and thyroid hormone receptor
(SMRT)_ID2, PR_H12 and BN2]. To verify the effect of
9-cis RA on the affinity of SMRT_ID2, the dose-re-
sponse curves were measured, and Fig. 3B shows that
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Fig. 2. Categorization of Peptides Based on the Effect of 9-cis RA on their Binding to RXR LBD
Sequence alignment of A, Coactivator peptides that do not bind to RXR LBD in the absence of ligand nor in the presence of
10 M 9-cis RA; B, coactivator peptides that equally bind to RXR LBD in the absence of ligand and in the presence of 10 M
9-cis RA ( log(MI)  0.1) and in addition show a significantly high fluorescence intensity ( 3500); C, coactivator and D,
corepressor peptides that show an increase in affinity for the RXR LBD upon addition of 10 M 9-cis RA [log(MI)  0.3].
Sequences are aligned manually by their coactivator motifs or corepressor motifs. The amino acids that are part of these motifs
are indicated in bold. The peptides in panels B and C/D are ordered by increasing fluorescence intensities in the absence and
presence of 9-cis RA, respectively. P.D. pept., Phage display peptide.
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the binding of SMRT_ID2 improves upon addition of
9-cis RA, i.e. the estimated Kd
app changes from 325 to
153 nM. It has been shown before that the second
interaction domain of SMRT binds to RXR in the
absence of ligand (36) and that a synthetic agonist
LG100268 induces SMRT binding to RXR (37). How-
ever, for the first time, we demonstrate that the affinity
of SMRT_ID2 increases upon addition of the natural
agonist, 9-cis RA. Similar peptide recruitment data
have been described for agonists in peroxisome pro-
liferator-activated receptor (38). From a structural per-
spective, knowing that H12 adopts the agonist posi-
tion in all 9-cis RA structures (6, 33, 39–41), this leads
to the question what the role of this helix is in the
Fig. 3. Peptide Binding Studied by Dose-Response Curves
Ligand-independent (dashed line) and ligand-dependent (10 M, solid line) dose-response curves of GST-hRXR with
RIP140_3 and 10 M 9-cis RA (panel A), SMRT_ID2 and 10 M 9-cis RA (panel B), and RIP140_3 and 10 M DHA (panel C). The
SEM value of two separate experiments (each experiment performed in duplicate) is indicated by the error bars.
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recruitment of the corepressor peptides. The only
crystal structure of an NR LBD with a corepressor
peptide [SMRT_ID2 (10)] showed that the peptide
binds in the coactivator binding groove and that H12 is
not in the agonist position. The N-terminal part of
SMRT_ID2 relocates H12 toward the N terminus of H3
and partially occupies the agonistic location of H12.
The recruitment of both coactivator and corepressor
peptides by 9-cis RA suggest that 9-cis RA induces a
conformational change in H12 that is stabilized in the
agonist position by coactivator peptides and in the
antagonist position by corepressor peptides.
The sequence alignment of the 13 coactivator pep-
tides and the four corepressor peptides that do not
bind in the absence of 9-cis RA, but do bind signifi-
cantly better to RXR in the presence of 9-cis RA, are
shown in Fig. 2, C and D, respectively. The sequence
alignment of the coactivator peptides shows that the
residue types at position 1 and 2 are less conserved
as compared with the residue types at these positions
for peptides that already bind to RXR in the absence
of 9-cis RA (Fig. 2B). This suggests that coactivator
peptides without a hydrophobic residue at position1
and without a positively charged or H-bond donating
residue at position 2 can only bind to the LBD when
H12 is sufficiently stabilized by the ligand. With a suf-
ficiently stable H12, the structural composition of the
peptides becomes less critical for binding to the re-
ceptor, i.e. more sequential variation of the peptides is
allowed.
Clustering of Peptide Recruitment Profiles of
Various RXR Ligands
Figure 1B shows the peptide recruitment profiles of a
total of 11 different ligands, and 9-cis RA is depicted
as a reference (solid black line). The 10 other ligands
include five fatty acids, three synthetic agonists (tar-
gretin, LG100268, LG100324), a homodimer antago-
nist (LG100754), and a RAR agonist TTNPB (Fig. 4).
Figure 1B clearly shows that some compounds induce
peptide association in a similar manner as 9-cis RA,
Fig. 4. Chemical Structures of RXR Compounds Used in This Study
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whereas other compounds induce peptide dissocia-
tion (negative log MI values). Dissociation of peptides
is confirmed by dose-response curves. For example,
Fig. 3C shows that the estimated Kd
app of RIP140_3
increases from 152 nM to 1129 nM upon addition of
DHA. This indicates that the firm binding of RIP140_3
in the absence of ligand can be antagonized by a
ligand such as DHA. This suggests that DHA destabi-
lized H12 and thereby altered the optimal conditions
for coactivator binding.
To identify which compounds induce identical or
unique peptide recruitment profiles, we performed a
hierarchical clustering (see Data Analysis in Materials
and Methods) on the 11 ligand-induced peptide re-
cruitment profiles (Fig. 5). The dendrogram of the hi-
erarchical clustering of these peptide recruitment pro-
files was used to determine a boundary to cluster
compounds that induce similar peptide recruitment
profiles. Figure 6 shows the resulting four different
clusters with the corresponding peptide recruitment
profiles of the individual compounds in these clusters.
On the basis of the shape of the peptide recruitment
profiles, we refer to these clusters as a dissociative
profile (1), silent profiles (2 and 3), and an associative
profile (4).
The natural ligand of RXR, 9-cis RA, clusters to-
gether with targretin, LG100268, LG100324, and
methoprene acid. These five compounds form the
largest cluster (Fig. 6, cluster 4, 9-cis RA; black line). All
compounds in this cluster improve the binding of co-
activator and corepressor peptides. The enhancement
of the binding of coactivator peptides is in agreement
with previous studies, which demonstrate that these
compounds act as agonists in RXR-mediated tran-
scription pathways (18, 42–44). The recruitment of the
four corepressor peptides by 9-cis RA (see above) is
also observed for the other agonists in this cluster.
The second largest cluster contains three com-
pounds that comprise three of the five fatty acids in the
ligand set (phytanic acid, oleic acid, and DHA). These
fatty acids deteriorate the binding of coactivator pep-
tides and enhance the binding of the corepressor pep-
tides NCoR_3L and, to a lesser extent, SMRT_ID2,
indicating that these fatty acids are classical antago-
nists. However, the corepressor peptide BN2 is dis-
sociated upon binding of these classical antagonists,
suggesting that BN2 binds as a coactivator via its
IXXLL motif.
The three remaining compounds are in clusters 2
and 3 (Fig. 6). Cluster 2 contains the homodimer an-
tagonist LG100754 and the fatty acid pentadecanoic
acid; cluster 3 contains the RAR agonist TTNPB.
Compared with the peptide recruitment profiles of the
compounds in clusters 1 and 4, these compounds
show negligible association or dissociation of most
peptides. This raises the question whether these com-
pounds actually bind to the receptor. Pentadecanoic
acid binds in the LBP as has been demonstrated by
x-ray (45). To determine the binding of LG100754 and
TTNPB, we performed a peptide recruitment compe-
tition assay with CBP_1 as peptide and 9-cis RA as
ligand. In the absence of LG100754, the EC50 of 9-cis
Fig. 5. Hierarchical Clustering of the Peptide Recruitment Profiles of 11 Different RXR Compounds Using a Hierarchical
Unweighted Clustering Routine with a Similarity Measure that Was Based on Cosine Correlation
Log(MI) data were normalized. The peptide recruitment profile of each ligand was represented as a row with 52 cells in the
distance matrix. Each cell is colored according to the normalized log(MI) value of the peptide with green being the highest log(MI)
and red the lowest log(MI) value. The vertical red line indicates the boundary that was chosen to define the separate clusters.
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RA is 3 nM (Fig. 7A). In the presence of 107 M
LG100754, the EC50 is increased to 43 nM, indicating
that LG100754 competes with 9-cis RA for the same
binding site. At even higher concentrations LG100754
(105 M), 9-cis RA is completely substituted by
LG100754. These data indicate that LG100754 binds
in the LBP but hardly affects the peptide binding pro-
file, i.e. the compound does not induce a conforma-
tional change in the LBD that results in a significant
dissociation or association of peptides.
The same competition assay was performed with
TTNPB (Fig. 7B). In the presence of increasing con-
centrations of TTNPB, the EC50 of 9-cis RA is hardly
changed, indicating that TTNPB does not compete
with 9-cis RA for the same binding site. Therefore we
omitted this compound from further discussion.
Correlation between the Peptide Recruitment
Profiles and Ligand Interaction Profiles
To investigate whether there are also differences be-
tween the binding modes of ligands, we first analyzed
the binding mode of all compounds that have been
cocrystallized with human (h)RXR LBD. These com-
pounds are the natural ligand 9-cis RA (6, 33, 39–41),
its isomer all-trans retinoic acid (46), the synthetic
agonists BMS649 (47) and L79 (48), and two fatty
acids, DHA (47) and pentadecanoic acid (PDA) (45).
The comparison of different ligand binding modes in
RXR has already been described for BMS649, 9-cis
RA, and DHA by Egea et al. (47). We used a different
approach by calculating so-called ligand-receptor in-
teraction profiles, which are believed to represent the
binding mode of the ligands. This facilitates the anal-
ysis of ligand binding in large sets of crystal structures
in an automatic manner. Figure 8 shows the ligand-
receptor interaction profiles of the six cocrystallized
ligands with 9-cis RA highlighted as solid black line
(see Materials and Methods for more details on the
methodology to calculate these profiles). The ligand-
receptor interaction profile describes the number of
contacts between each residue in the LBD and the
ligand. Residues in the LBD have been assigned so-
called 3D numbers to allow easy comparison of dif-
ferent structures (49). It should be noted that the crys-
tal structures used in this study are derived from
multiple independent sources, which could lead to
differences in binding modes of the ligand in the LBP
Fig. 6. The Peptide Recruitment Profiles of 11 RXR Compounds Grouped by the Hierarchical Clustering Method (Fig. 5)
Cluster 1 contains oleic acid, phytanic acid, and DHA. Cluster 2 contains PDA and LG100754. Cluster 3 contains TTNPB.
Cluster 4 contains 9-cis RA, methoprene acid, LG100268, LG100324, and targretin. Each line represents the log(MI) values for
all peptides for one compound.
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in the different crystals. We therefore averaged the
contacts between 9-cis RA and hRXR in the five
available crystal structures (6, 33, 39–41) and calcu-
lated the SE of the average number of contacts in the
ligand-receptor interaction profiles (supplemental Fig.
2 published as supplemental data on The Endocrine
Society’s Journals Online web site at http://mend.en-
dojournals.org). This figure shows that the SE is rela-
tively small, indicating that the binding modes of 9-cis
RA as resolved from multiple independent sources is
highly similar. Figure 8 shows that the six ligands have
interactions with residues in H3, H5, the -sheet, H7,
Fig. 7. Competition Studies of LG100754 and TTNPB with 9-cis RA
Dose-response curves of 9-cis RA were measured in a TR-FRET assay with GST-hRXR LBD and CBP_1 (0.1 M) in the
presence of increasing concentrations of LG100754 (panel A) and TTNPB (panel B). The SEM of two separate experiments, each
performed in duplicate, is indicated by the error bars.
Fig. 8. Ligand-Receptor Interaction Profiles of Compounds in hRXR Crystal Structures
A ligand-receptor interaction profile describes for each position in the LBD the number of interactions with the ligand. The
profile of 9-cis RA is highlighted as a solid black line. The profiles of the five other compounds that are cocrystallized with hRXR
(all-trans retinoic acid, DHA, PDA, BMS649, and L79) are shown in light gray. The secondary structures of the LBD that correspond
with the 3D numbers are displayed below the graph. The average number of contacts and the SEM in five available crystal
structures (6, 33, 39–41) of hRXR with 9-cis RA are given in supplemental Fig. 2.
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and H10. The most important ligand binding positions
are 335, 339, 556 and 1057, which is in agreement
with other members of the NR family (50). The ligand-
receptor interaction profiles of the six compounds in
Fig. 8 show that the number of contacts between
various residues and the ligand differ among the six
ligands. This suggests that the ligands have distinct
binding modes, which was already described by Egea
et al. (47) for three of these six ligands. We therefore
performed a hierarchical clustering (see Data Analysis
in Materials and Methods) on the six ligand-receptor
interaction profiles, which resulted in four different
clusters. The corresponding ligand-receptor interac-
tion profiles of the individual compounds in these clus-
ters are shown in Fig. 9.
9-cis RA, BMS649, and L79 form the largest cluster
(Fig. 9, cluster 4, 9-cis RA; black line). The compounds
in this cluster are described as agonists. BMS649 and
L79 are synthetic agonists that better fill the LBP as
compared with 9-cis RA. The natural ligand only oc-
cupies 59% of the total LBP volume (51). One part of
the pocket that is not occupied by 9-cis RA is near
residues at 3D positions 548 and 549 (W305 and N306
in hRXR, respectively). The synthetic agonists are
designed to better fill this side of the pocket, which is
reflected in the ligand-receptor interaction profiles that
show higher number of contacts between the ligand
and positions 549 and 552 (Fig. 9, cluster 4) than that
observed in the other clusters.
The three remaining clusters each contain one li-
gand (Fig. 9, cluster 1–3). Cluster 1 contains all-trans
retinoic acid, which is the natural ligand of RAR. The
x-ray structure of this compound with RXR crystal-
lized as a tetramer with H12 of each monomer in the
coactivator groove of the adjacent monomer (46). The
formation of a tetramer also led to a displacement of
the N-terminal part of H3 and the C-terminal part of
H10. Therefore, the ligand-receptor interaction profile
of this compound is dissimilar to the other profiles.
Clusters 2 and 3 both contain a fatty acid, PDA and
Fig. 9. Ligand-Receptor Interaction Profiles of the Compounds in hRXR Crystal Structures Grouped by Hierarchical Clustering
(Unweighted, Similarity by Correlation)
Cluster 1 contains all-trans-RA. Cluster 2 and 3 contain PDA and DHA, respectively. Cluster 4 contains 9-cis RA, BMS649, and
L79. Each line represents the ligand-receptor interaction profile of a compound.
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DHA, respectively. The major difference in the ligand-
receptor interaction profile that separates these two
clusters is the high number of contacts of DHA (47)
with position 1057 (Fig. 9, cluster 3), which is not
observed in the ligand-receptor interaction profiles of
any other compound. Clustering of the ligand-interac-
tion profiles of these six ligands suggests that there
are four different binding modes of RXR compounds in
the available crystal structures, which can be detected
by this method.
Because the RXR crystal structure data are limited
to six compounds, of which only two are in the peptide
recruitment data set, we manually modeled each of
the 10 RXR compounds that were profiled in the
peptide recruitment assay and studied the interaction
between the receptor and the ligand by MD (see MD
Stimulations of Manually Docked Compounds in the
RXR LBD in Materials and Methods). TTNPB was
excluded from the initial set, because this compound
does not bind to the RXR LBD (see above). Figure 10
shows the ligand-receptor interaction profiles that
were calculated from model structures of the 10 com-
pounds. To identify how unique or similar the different
binding modes of the ligands in the LBP are, we per-
formed the same clustering procedure (see Data Anal-
ysis in Materials and Methods) on the ligand-receptor
interaction profiles as was applied to the profiles of the
compounds in the crystal structures. From the den-
drogram (data not shown) two distinct ligand-receptor
interaction profile clusters could be identified. The cor-
responding profiles of the individual compounds in
both clusters are shown in Fig. 11.
The first cluster contains oleic acid, DHA, phytanic
acid, PDA, and LG100754. The second cluster con-
tains all agonists: 9-cis RA (black line), targretin,
LG100324, LG100268, and methoprene acid. A
clear difference between the two clusters is the
number of contacts of the compounds with residues
in the C-terminal part of H10, in particular 3D posi-
tions 1057 and 1061, which was already observed
by Egea et al. in comparing the ligand binding
modes in crystal structures with 9-cis RA, DHA,
BMS649, and oleic acid (47). In general, compounds
from the agonist cluster have a lower number of
contacts with these residues than the compounds in
the other cluster. To reveal a structural explanation
for the differences in binding mode of compounds
from the agonist cluster and the other cluster, we
superposed hRXR crystal structures, each with a
compound from one of the clusters (9-cis RA from
the agonist cluster and DHA from the other cluster;
Fig. 12). Figure 12 clearly shows the differences of
interaction between each of the two compounds
and the H10 region. Although the side chain of cys-
teine 1057 (corresponding to residue 432 in hRXR)
is in the same orientation in both structures, leucine
1061 (436 in hRXR) showed a movement of its side
chain. In the crystal structure with DHA (47), the side
chain of this leucine is shifted toward H12, whereas
in the crystal structure with 9-cis RA this residue is
pointing into the pocket of the LBP. The movement
of this side chain toward H12 suggests a destabili-
zation of this helix. This destabilization is reflected in
the DHA-induced peptide recruitment profile, which
shows a dissociation of most coactivators and con-
firms destabilization of H12 by interaction of ligands
with residue 1061 (436 in hRXR).
The clustering of the ligand-receptor interaction pro-
files does not distinguish between compounds that
were dissociative (DHA, oleic acid, and phytanic acid)
or silent (LG100754 and PDA) in their induced peptide
recruitment profiles. We therefore compared the indi-
vidual ligand-receptor interaction profile of LG100754
with the profiles of representative compounds from
the two other clusters (9-cis RA for the associative,
DHA for the dissociative peptide recruitment cluster;
Fig. 11). In addition, the binding mode of LG100754
was compared with that of 9-cis RA by superposition
of the x-ray RXR structure with 9-cis RA [1FM6 (39)]
and the coordinate set of RXR with LG100754 of the
frame with the lowest interaction energy (Fig. 13). In-
terestingly, the binding mode of LG100754 in the LBP
is different from 9-cis RA in three areas. The first area
is near the tryptophan at position 548 (3D no. 305 in
Fig. 10. Ligand-Receptor Interaction Profiles of 10 RXR Compounds that Were Modeled in the hRXR LBD and Were Tested in
the Peptide Recruitment Profiling
TTNPB was excluded from this set because it was shown that it does not bind to the RXR LBD. The secondary structures
of the LBD that correspond with the 3D numbers are displayed below the graph.
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hRXR). The propoxy group of LG100754 points to-
ward this residue, whereas the other ligands do not
occupy this space. This leads to a higher number of
contacts in the ligand-receptor interaction profile of
LG100754 at 3D residue positions 548, 549, 552, and
553 (corresponding to residues 305, 306, 309, and 310
in hRXR) compared with the profiles of the other two
compounds (DHA and 9-cis RA, Fig. 11). The second
area is in the N-terminal part of H3. The tetra-hy-
dronaphthalene moiety of the homodimer antagonist
is shifted toward this part of the LBD, leading to a
higher number of contacts with 3D residue positions
331 and 332 (corresponding to residues 264 and 265
in hRXR). The third area comprises residues in H7.
The binding mode of LG100754 shows a lower num-
ber of contacts between LG100754 and 3D residue
positions 738 and 739 (corresponding to residues 345
and 346 in hRXR) than 9-cis RA and DHA.
DISCUSSION
We hypothesized that the binding mode of a ligand in
the LBP determines the conformation at the receptor
surface through allosteric coupling. For this purpose,
we determined whether compounds that bind differ-
ently in the LBP act differently in cofactor recruitment,
by comparing the clustering based on ligand-receptor
interaction profiles with the clustering of the com-
pounds based on peptide recruitment profiles. We
observed two distinct binding modes of ligands in the
LBP by means of clustering of the ligand-receptor
interaction profiles whereas we observed three distinct
conformations of the RXR LBD by means of cluster-
ing of the peptide recruitment profiles. These three
distinct conformational changes of the RXR LBD can
be described as an associative, dissociative, or silent
peptide recruitment profile. We observed that the five
Fig. 11. The Ligand-Receptor Interaction Profiles of 10 RXR Compounds that Were Calculated from the Structures Generated
by Molecular Modeling
The profiles were grouped following hierarchical clustering (unweighted, similarity by correlation). Cluster 1 contains oleic acid,
DHA (black line), phytanic acid, PDA, and LG100754 (black line). Cluster 2 contains 9-cis RA (black line), targretin, LG100324,
LG100268, and methoprene acid. Each line represents the ligand-receptor interaction profile of a compound. Profiles of DHA and
LG100754 are indicated by arrows.
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compounds in the associative peptide recruitment
profile cluster are the same five compounds in one of
the two clusters of the ligand-receptor interaction pro-
files. This indicates that there is indeed a correlation
between the binding mode of a ligand and the confor-
mation at the surface. However, the ligand-receptor
interaction profiles do not yet discriminate between
compounds that induce minor conformational
changes (silent peptide recruitment profile) and com-
pounds that destabilize H12 (dissociative peptide re-
cruitment profile).
In this discussion we will focus on two issues. First,
we discuss how well the data from a peptide recruit-
ment assay reflect the effect of a compound in in vitro
transactivation assays as described in the literature.
Second, we give a structural explanation for the three
distinct conformational changes at the RXR surface,
i.e. the structural mechanism underlying the associa-
tive, dissociative, and silent peptide recruitment
profile.
Peptide Recruitment Assay vs. in Vitro
Transactivation Assay
Current models of NR activation suggest that agonist
compounds promote the association of a coactivator
and the dissociation of a corepressor. Agonist com-
pounds stabilize H12 in an active conformation,
thereby facilitating the binding of a coactivator protein
and reducing the affinity of corepressors. On the other
hand, antagonists displace H12 from the active posi-
tion, which results in enhancement of the binding of
corepressors and reduction of the binding of coacti-
vators. Finally, the so-called selective nuclear receptor
modulators (SNRMs) induce such a conformation of
H12 that both coactivator and corepressor can bind
(52, 53). This may lead to an increase or decrease in
gene transcription depending on the concentration of
coactivators and corepressors in a cell. In this study,
however, the coactivators and corepressors are rep-
resented by short peptide fragments, and the ligand-
induced recruitment or dissociation of these frag-
ments was measured by peptide recruitment. This
raises two questions:
How Well Does a Peptide Recruitment Profile
Reflect the Effect of a Compound in a Cell?
We observed that compounds in the associative clus-
ter recruited not only coactivator peptides, but also
corepressor peptides. In the context of the above de-
scribed models for NR activation, our data indicate
that 9-cis RA and other RXR agonists are not classical
agonists, but actually act as SNRMs. The observation
that these SNRMs induce coactivator and corepressor
binding suggests that these compounds only partially
stabilize H12 in the agonist position. This offers H12
sufficient conformational freedom to take the antago-
nist position in the presence of a corepressor peptide
and the agonist position in the presence of a coacti-
vator peptide. The final agonist or antagonist response
of the compound in a particular cell type depends on
the concentrations of cofactors in this cell type (52,
53). Because several studies have shown that these
compounds act as agonists in various cell-based as-
says (18, 42–44), this suggests that these cell types
Fig. 12. Comparison of the Binding Modes of DHA (orange)
and 9-cis RA (green)
All chains from RXR crystal structures with 9-cis RA (6,
33, 39–41) or DHA (47) were superposed, and the side chains
of the cysteines at 3D position 1057 and the leucines at 3D
position 1061 are shown. The secondary structure represen-
tation is based on the backbone of 1FM6 (39), H10, Helix 10;
H12, helix 12.
Fig. 13. Comparison of the Binding Modes of LG100754
(cyan) and 9-cis RA (green)
The coordinate set of RXR with LG100754 of the frame
with the lowest interaction energy was superposed on the
RXR crystal structure with 9-cis RA (39). The three areas
where differences in ligand binding are observed are indi-
cated with one representative residue for each area. The
secondary structure representation is based on the back-
bone of 1FM6 (39). H3, Helix 3; H5, helix 5; H7, helix 7.
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have a higher concentration of coactivators than
corepressors.
Compounds in the dissociative cluster reduced the
binding of coactivator peptides whereas they in-
creased the binding of corepressor peptides, i.e. the
profile of a typical antagonist. This suggests that these
compounds behave as full antagonists in cell-based
assays. However, several studies show that fatty acids
activate rather than inhibit RXR-mediated gene tran-
scription (19, 21). One possible explanation is that
concentrations of corepressors in these cell-based
assays may have been too low to compete with high
levels of coactivators and that other cell types with
high corepressor concentrations are needed to dem-
onstrate the antagonist activity of fatty acids.
Compounds in the silent cluster did not induce a
change in binding affinity for either coactivator or core-
pressor peptides, suggesting that there will be no
change in basal gene transcription. Most likely, these
compounds will be silent antagonists due to compe-
tition with the natural ligand 9-cis RA under physiolog-
ical conditions.
In general, the correlation between the peptide re-
cruitment profile of a compound and its cellular effect
should be carefully interpreted, because it cannot be
excluded that the ligand induced a conformational
change at other locations at the surface of the LBD
that are not detected by means of the current peptide
recruitment assay. For example, it has been shown
that ligands also induce conformational changes that
lead to a different interaction with dimmer partners,
which results in a different cellular response (54, 55).
We also cannot exclude that peptides in the peptide
recruitment profile bind outside the classical coactiva-
tor binding groove, as has been suggested to alterna-
tive peptide binding positions as has been described
for the farnesoid X receptor (56), ER (57), and Nurr1
(58).
HowWell Does the Peptide Recruitment Assay Re-
flect the Interaction between a Full-Length NR and
a Full-Length Cofactor in Vitro? In general, we
observed that our peptide binding data agree well with
the binding data of full-length cofactors that have been
described in the literature. For example, the full-length
cofactor recruitment of SRC3, FHL2, SRC1, and
RIP140 (33, 34, 59, 60) is reflected by the recruitment
of peptides derived from these coactivators. In addi-
tion, we noticed that the coactivator peptides can be
classified as peptides that already strongly bind to the
LBD in the absence of an agonist, peptides that only
bind in the presence of a ligand, and peptides that do
not bind. Peptides with a hydrophobic residue at po-
sition 1 in the peptide sequence did already bind
strongly to the LBD in the absence of ligand, indicating
that these coactivators force H12 in an agonist posi-
tion, even in the absence of ligand. This suggests that
these RXR-cofactor complexes are continuously ac-
tive in gene transcription even without ligand.
Peptides that lack a hydrophobic residue at position
1 did bind only to the RXR LBD in the presence of
9-cis RA. This indicates that the cellular action of these
coactivators is activated only when 9-cis RA is
present. This suggests that these coactivators may be
more important for ligand-induced gene transcription
processes as compared with coactivators that always
bind to RXR. However, binding experiments with full-
length cofactors and NRs are needed to study this in
more detail.
Peptide Recruitment Profiles and Underlying
Structural Mechanisms
Associative and Dissociative Peptide Recruitment
Profiles. To determine the structural mechanism
underlying the induced association/dissociation of
peptides, we focused on compounds that induce an
associative peptide recruitment profile and on com-
pounds that induce a dissociative peptide recruitment
profile. Comparison of the ligand-receptor interaction
profiles of both clusters revealed that the compounds
that induce a dissociative peptide recruitment profile
have a significant higher number of contacts with res-
idues 1057 and 1061 (3D nos. C432 and L436 in
hRXR, respectively) in the C-terminal part of H10 (47).
This suggests that compounds that are in contact with
the C terminus of H10 destabilize the agonistic binding
mode of H12, resulting in dissociation of coactivators
and therefore act as antagonists. A similar mechanism
for antagonism has been described for ER (61). The
differences in binding of 9-cis RA and DHA near the C
terminus of H10 were already observed by Egea et al.
(47), but for the first time we were able to link these
structural interactions between ligand and receptor
with the ligand-induced association and dissociation
of coactivator and corepressor peptides.
Silent Peptide Recruitment Profile. Clustering of
the ligand-receptor interaction profiles could not dis-
tinguish between compounds that induced a dissocia-
tive or silent peptide recruitment profile. However, the
proposed ligand binding mode of LG100754 (Fig. 13)
shows that there are three plausible explanations for
the observation that this compound acts as a silent
antagonist.
1) The shift of LG100754 toward H3 excludes a high
number of contacts with the C-terminal part of H10,
which is needed to destabilize H12 (see above).
2) W548 in H5 is described in stabilizing H12 via a
water molecule (6), and therefore the position of this
residue is important. Ligands protruding into the area
near this residue could disrupt the stabilization of H12,
as was already shown by the docking of the retinoid
antagonist HX503 (6). The binding mode of LG100754
suggests that the orientation of the propoxy group
toward W548 is such that H12 is neither stabilized nor
destabilized. This hypothesis is strengthened by the
observation that ligands that are identical to
LG100754, but have a methoxy or ethoxy group in-
stead of a propoxy group, act as agonists or partial
agonists, respectively (54, 55).
3) The N-terminal part of H3 is described in direct
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interactions with H12 and the C-terminal part of H11.
In addition, an analysis of ligand-receptor contacts in
all NR LBDs revealed that partial agonists interact
more strongly with this part of H3 (50). LG100754 has
a significant higher number of contacts with H3 that
could destabilize H12. Together, this suggests that the
homodimer antagonist has a unique binding mode,
which neither stabilizes nor destabilizes H12 and re-
sults in a minor effect on peptide binding in the peptide
recruitment assay.
Final Conclusion
In summary, this work shows for one class of com-
pounds that there is a correlation between the binding
mode of a ligand (represented by a ligand-receptor
interaction profile) and the conformational change it
induces at the surface of the RXR LBD (represented
by a peptide recruitment profile). We therefore con-
clude that clustering of ligand-receptor interaction
profiles is a very useful tool to discriminate com-
pounds that may induce different conformations. We
also conclude that compounds can be easily classified
by their peptide recruitment profiles. However, the
translation to a cellular effect is difficult. These peptide
recruitment profiles suggest that, depending on the
cofactor concentration in the cell, five well-known
RXR agonists actually behave like SNRMs, whereas
three weak agonistic fatty acids may act as antago-
nists and two compounds act as silent antagonists.
We therefore envision that the methods described in
this paper can be of great value for drug design. With
these methods new compounds can be profiled based
on their ligand binding properties and their peptide
recruitment properties. Moreover, the combination of
both profiles will lead to useful insights in the working
mechanism of a NR LBD, which in turn aid the design
of compounds with a desired effect.
MATERIALS AND METHODS
Plasmid Construction and Protein Purification
cDNA coding for the ligand-binding domain of human RXR
(hRXR, amino acids 221–462) was cloned into the EcoRI
and XHoI sites of pGEX-4T-1 (Amersham, Piscataway, NJ).
The protein was expressed as a fusion protein with glutathi-
one S-transferase (GST) in Escherichia coli DH5 and purified
by affinity chromatography.
Ligands
Figure 4 shows the structures of the ligands that were used
in the peptide recruitment assay. Oleic acid, phytanic acid,
DHA, pentadecanoic acid (PDA), methoprene acid, TTNPB,
and 9-cis RA (all purchased from Sigma-Aldrich) and
LG100324, LG100268, LG100754, and targretin (all synthe-
sized in house) were diluted in dimethyl sulfoxide to a final
concentration of 10 mM.
Peptides
Supplemental Table 1, published as supplemental data on
The Endocrine Society’s Online Journals web site, shows the
sequences of the 52 N-terminal biotinylated peptides (Neo-
system S.A., Strasbourg, France) derived from 15 different
cofactors, five NRs, and various phage display peptide librar-
ies (28, 62). Thirty three peptides contain the LXXLL coacti-
vator motif whereas three peptides possess a FXXLF motif
and two peptides have a FXXLY motif. Twelve repressor
peptides in the set are described by the consensus sequence
(L/I/V)XXX(L/I/V)XXX(L/I/V), whereas two repressor peptides
(NcoR_4 and NCoR_4M) lack this consensus sequence. Due
to similarity between the consensus sequences of a coacti-
vator and corepressor motif, it is possible that some peptides
contain both coactivator and corepressor motifs.
TR-FRET Assay
A TR-FRET assay was performed with 52 peptides in the
absence and presence of ligand. Each reaction mixture (pH
7.2) contains 50 mM Tris, 50 mM KCl, 1 mM EDTA, 1 mM
dithiothreitol, 0.1 mg/ml BSA, 10 nM RXR LBD, 0.1 M
biotinylated peptide, 10 M ligand, 8 nM allophycocyanin-
labeled Streptavidin (PerkinElmer Life Sciences, Boston, MA),
and 1.25 nM LANCE Eu-W1024-labeled anti-GST antibody
(PerkinElmer Life Sciences). Each experiment was carried out
in duplicate in 384-well plates. Plates were centrifuged and
incubated for 24 h at 4 C. Fluorescence at 665 nm was
measured on a Victor (Wallac, Inc., Gaithersburg, MD).
To directly visualize the effect of a ligand on recruitment of
the different peptides, the MI was calculated, i.e. the ratio
between the fluorescence intensity in the presence of a ligand
and the fluorescence intensity in the absence of ligand. An MI
of 2.0 indicates a 2-fold increase of the amount of peptide
bound, whereas a MI of 0.5 indicates a 2-fold decrease in the
amount of peptide bound. This nonlinear behavior was trans-
lated into a linear positive signal for an increase in peptide
binding and a linear negative signal for a decrease in peptide
binding by calculating the 10log(MI). Log(MI) values above
zero indicate recruitment of peptides and thus an associative
effect of the ligand on peptide binding. In contrast, negative
values indicate dissociation of peptides and therefore a dis-
sociative effect of the compound on peptide binding. A
log(MI) value of around zero means that a peptide does not
bind and/or that the binding is not changed by the ligand.
To determine the apparent Kd values of specific peptides,
the binding curves were determined in a peptide concentra-
tion range between 0.1 nM and 1 M. Calculations were
performed in GraphPad Prism (GraphPad Software, Inc., San
Diego, CA; nonlinear regression curve fit, one-site binding
model). To determine EC50 values of ligands, we measured
ligand dose-response curves with ligand concentrations
ranging from 31.6 pM to 1 M.
MD Simulations of Manually Docked Compounds in the
RXR LBD
MD simulations were performed using QUANTA/CHARMm
(version 31b; Ref. 63) following a protocol that was described
previously by Kouwijzer et al. (64). The hRXR LBD of 1FM6
(chain A) was selected as template structure. The initial bind-
ing modes of six ligands were obtained from available x-ray
structures of either hRXR or hRXR by superposition of the
structures onto the template structure. The superposed
hRXR structure with DHA [1MV9 (47)] was used to construct
the initial binding mode of phytanic acid, and the superposed
hRXR structure with LG100268 (37) was used to model
LG100754, LG100324, and targretin (supplemental Table 2,
published as supplemental data on The Endocrine Society’s
Online Journals web site). The complexes were protonated,
charges were assigned, and ligand atom types and bond
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orders were corrected. The MD run started with a heating
phase of 10 psec, followed by a 100-psec run at 400 K during
which time the coordinate sets were saved every picosec-
ond. These coordinate sets were energy minimized, and for
each of these 100 frames the average interaction energy
between ligand and protein was calculated. The 10 coordi-
nate sets with the lowest average interaction energy were
used to calculate an average ligand-receptor interaction
profile.
Ligand-Receptor Interaction Profiles
The number of contacts between ligands and residues in the
RXR LBD was calculated by the Automatic Residue Extrac-
tion System (ARES), as was previously described for the
analysis of ligand binding in all NR LBDs (50). For each unique
receptor-ligand combination, ARES automatically creates a
so-called ligand-receptor interaction profile. A contact is in-
cluded in the profile when the distance between the Van der
Waals’ surfaces of the atoms of a ligand and a residue is less
than 1 Å. A unique number is assigned to each residue
position that is structurally conserved within the family of the
NR LBDs (49). This 3D number starts with one or two digits
that indicate the helix number; similarly B and L reflect resi-
dues in the -sheet and loops, respectively. Residues that are
not structurally conserved and therefore do not have a 3D
number all got the number zero. Contacts in multiple copies
of the same LBD-ligand complex were normalized. If, for
example, a LBD-ligand complex is observed two times in one
PDB file and three times in another, all contacts in all five
chains are summed up and divided by 5.
Data Analysis
The TR-FRET assay and the contact analysis by ARES
yielded peptide recruitment profiles and ligand-receptor in-
teraction profiles, respectively. Spotfire DecisionSite (Spot-
fire, Somerville, MA) was used to cluster both types of profiles
by a hierarchical unweighted clustering routine with a simi-
larity measure that was based on (cosine) correlation. Result-
ing dendrograms were used to determine the boundary to
separate clusters.
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